Biontech Se Stock Today
| BNTX Stock | USD 86.17 0.23 0.27% |
Performance0 of 100
| Odds Of DistressLess than 9
|
BioNTech is trading at 86.17 as of the 19th of April 2024; that is -0.27 percent decrease since the beginning of the trading day. The stock's open price was 86.4. BioNTech has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for BioNTech SE are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2019 | Category Healthcare | Classification Health Care |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 240.99 M outstanding shares of which 3.08 M shares are currently shorted by private and institutional investors with about 4.33 trading days to cover. More on BioNTech SE
Moving together with BioNTech Stock
| 0.72 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.77 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
Moving against BioNTech Stock
| 0.56 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.51 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.48 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 13th of May 2024
BioNTech Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioNTech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioNTech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO CoFounder | Ugur MD | ||||
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Management, Computers, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering BioNTech report their recommendations after researching BioNTech's financial statements, talking to executives and customers, or listening in on BioNTech's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering BioNTech SE. The BioNTech consensus assessment is calculated by taking the average forecast from all of the analysts covering BioNTech. | |||||
BioNTech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to BioNTech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioNTech's financial leverage. It provides some insight into what part of BioNTech's total assets is financed by creditors.
| |||||
BioNTech SE (BNTX) is traded on NASDAQ Exchange in USA. It is located in An der Goldgrube 12, Mainz, Germany, 55131 and employs 6,133 people. BioNTech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 20.82 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioNTech's market, we take the total number of its shares issued and multiply it by BioNTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioNTech SE conducts business under Biotechnology sector and is part of Health Care industry. The entity has 240.99 M outstanding shares of which 3.08 M shares are currently shorted by private and institutional investors with about 4.33 trading days to cover.
BioNTech SE currently holds about 9.33 B in cash with 5.37 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.3.
Check BioNTech Probability Of Bankruptcy
Ownership AllocationBioNTech holds a total of 240.99 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 62.84 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioNTech Ownership Details
BioNTech Stock Price Odds Analysis
Based on a normal probability distribution, the odds of BioNTech jumping above the current price in 90 days from now is about 98.0%. The BioNTech SE probability density function shows the probability of BioNTech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days BioNTech has a beta of 0.6458 suggesting as returns on the market go up, BioNTech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding BioNTech SE will be expected to be much smaller as well. Additionally, bioNTech SE has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of BioNTech to move above the current price in 90 days from now is about 98.0 (This BioNTech SE probability density function shows the probability of BioNTech Stock to fall within a particular range of prices over 90 days) .
BioNTech Stock Institutional Holders
Institutional Holdings refers to the ownership stake in BioNTech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioNTech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioNTech's value.| Instituion | Recorded On | Shares | |
| Deutsche Bank Ag | 2023-09-30 | 546.5 K | |
| Voloridge Investment Management, Llc | 2023-09-30 | 530.5 K | |
| Millennium Management Llc | 2023-09-30 | 498.4 K | |
| Clearbridge Advisors, Llc | 2023-09-30 | 484.1 K | |
| Dekabank Deutsche Girozentrale | 2023-12-31 | 425.1 K | |
| First Trust Advisors L.p. | 2023-12-31 | 416.9 K | |
| Gilder Gagnon Howe & Co Llc | 2023-12-31 | 359.7 K | |
| Bamco Inc | 2023-12-31 | 242.3 K | |
| Fmr Inc | 2023-09-30 | 237.8 K | |
| Baillie Gifford & Co Limited. | 2023-12-31 | 8.7 M | |
| Primecap Management Company | 2023-12-31 | 4.8 M |
BioNTech Historical Income Statement
BioNTech SE Income Statement is one of the three primary financial statements used for reporting BioNTech's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of BioNTech SE revenue and expense. BioNTech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, BioNTech's Net Income Applicable To Common Shares is fairly stable compared to the past year. View More FundamentalsBioNTech Stock Against Markets
Picking the right benchmark for BioNTech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in BioNTech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for BioNTech is critical whether you are bullish or bearish towards BioNTech SE at a given time. Please also check how BioNTech's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioNTech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
BioNTech Corporate Management
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Katalin Kariko | Senior Therapies | Profile | |
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | Vice Strategy | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Siegbert Kloos | Datand Digital | Profile | |
| Sierk Poetting | COO MD | Profile |
How to buy BioNTech Stock?
Before investing in BioNTech, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in BioNTech. To buy BioNTech stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of BioNTech. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase BioNTech stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located BioNTech SE stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased BioNTech SE stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as BioNTech SE, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy BioNTech Stock please use our How to Invest in BioNTech guide.
Already Invested in BioNTech SE?
The danger of trading BioNTech SE is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of BioNTech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than BioNTech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile BioNTech SE is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.07 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.